Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q3 2017 · 10-Q
Revenue$334.15M$334.15M+19.4% vs Q3 2016 Net Income-$12.53M-$12.53MN/M vs Q3 2016 EPS Diluted-$0.07-$0.07N/M vs Q3 2016 Operating Income-$13,727,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,190,000N/M Margins · derivedOperating margin-4.1%+17.4 pt vs Q3 2016
Net margin-3.7%+9.6 pt vs Q3 2016
ended Sep 30, 2017 · filed Oct 31, 2017 · 31 d after period end